A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Principal Investigator
Martin GleaveOverview
Body Locations and Systems
Prostate CancerClinicalTrials.gov#
NCT01946204Status
Closed for RecruitmentStudy Start/End
Sep 3, 2013 to May 31, 2018Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Maureen Palmer, Study CoordinatorPhone
604-875-5675Email Address
maureen.palmer@vch.caPurpose of Study
The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.